22 related articles for article (PubMed ID: 32683851)
1. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.
Tufail M; Cui J; Wu C
Am J Cancer Res; 2022; 12(7):2920-2949. PubMed ID: 35968356
[TBL] [Abstract][Full Text] [Related]
2. CMBs carrying PTX and CRISPR/Cas9 targeting
Peng S; Cai J; Bao S
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34590151
[TBL] [Abstract][Full Text] [Related]
3. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
Lynch BJ; Guinee DG; Holden JA
Hum Pathol; 1997 Oct; 28(10):1180-8. PubMed ID: 9343325
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinical value of miR-27a in serum of patients with skin squamous cell carcinoma.
Wang H; Wang S; Chen F; Zhang C; Zhang X; Sun Y
J BUON; 2020; 25(5):2515-2522. PubMed ID: 33277877
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha expression in ductal carcinoma in situ of the breast: a preliminary study.
Shpitz B; Bomstein Y; Zehavi T; Bernheim J; Liverant S; Kaufman Z; Buklan G; Klein E
Hum Pathol; 2000 Oct; 31(10):1249-54. PubMed ID: 11070118
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
8. Using specific cytotoxics with a targeted mind.
Di Leo A; Claudino WM; Pestrin M; Licitra S; Biganzoli L
Breast; 2007 Dec; 16 Suppl 2():S120-6. PubMed ID: 17720501
[TBL] [Abstract][Full Text] [Related]
9. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
[TBL] [Abstract][Full Text] [Related]
10. The significance of heregulin in breast cancer tumor progression and drug resistance.
Lupu R; Cardillo M; Cho C; Harris L; Hijazi M; Perez C; Rosenberg K; Yang D; Tang C
Breast Cancer Res Treat; 1996; 38(1):57-66. PubMed ID: 8825123
[TBL] [Abstract][Full Text] [Related]
11. The expression and prognostic significance of Topo-II and c-erbB-2 in breast cancer.
Hua S; Chuanbo F; Zhonglin W; Shuangjiu Z; Xinwen Z
Minerva Med; 2020 Jul; ():. PubMed ID: 32683851
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
